Sagimet Biosciences Inc [SGMT] stock prices are up 0.23% to $8.75 at the moment. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The SGMT shares have gain 3.55% over the last week, with a monthly amount drifted -7.60%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Sagimet Biosciences Inc [NASDAQ: SGMT] stock has seen the most recent analyst activity on August 11, 2025, when Wedbush initiated its Outperform rating and assigned the stock a price target of $28. On July 24, 2025, Canaccord Genuity initiated with a Buy rating and assigned a price target of $28 on the stock. Oppenheimer started tracking the stock assigning a Outperform rating and suggested a price target of $30 on December 06, 2024. UBS initiated its recommendation with a Buy and recommended $12 as its price target on November 12, 2024. Goldman downgraded its rating to Neutral for this stock on June 28, 2024, and downed its price target to $6. In a note dated May 02, 2024, H.C. Wainwright initiated an Buy rating and provided a target price of $32 on this stock.
The stock price of Sagimet Biosciences Inc [SGMT] has been fluctuating between $1.73 and $11.41 over the past year. Currently, Wall Street analysts expect the stock to reach $6 within the next 12 months. Sagimet Biosciences Inc [NASDAQ: SGMT] shares were valued at $8.75 at the most recent close of the market. An investor can expect a potential drop of -31.43% based on the average SGMT price forecast.
Analyzing the SGMT fundamentals
To continue investigating profitability, this company’s Return on Assets is posted at -0.39, Equity is -0.35 and Total Capital is -0.47. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.0.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 8.51 points at the first support level, and at 8.28 for the second support level. However, for the 1st resistance point, the stock is sitting at 9.10, and for the 2nd resistance point, it is at 9.44.
Ratios To Look Out For
It’s worth pointing out that Sagimet Biosciences Inc [NASDAQ:SGMT]’s Current Ratio is 20.26. As well, the Quick Ratio is 20.26, while the Cash Ratio is 9.01.
Transactions by insiders
Recent insider trading involved Happel David, President & CEO, that happened on Jul 21 ’25 when 65478.0 shares were sold. Chief Medical Officer, Martins Eduardo Bruno completed a deal on Jul 21 ’25 to sell 8277.0 shares. Meanwhile, General Counsel and CCO Rozek Elizabeth sold 10780.0 shares on Jul 21 ’25.
